1 / 5

Valsartan in Acute Myocardial Infarction Trial Investigators

VALIANT Trial. Valsartan in Acute Myocardial Infarction Trial Investigators . Presented at American Heart Association Scientific Sessions 2003 Marc A. Pfeffer, et al. N Engl J Med 2003;349:1893-906. VALIANT Trial.

falala
Download Presentation

Valsartan in Acute Myocardial Infarction Trial Investigators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. VALIANT Trial Valsartan in Acute Myocardial Infarction Trial Investigators Presented at American Heart Association Scientific Sessions 2003 Marc A. Pfeffer, et al. N Engl J Med 2003;349:1893-906

  2. VALIANT Trial 14,703 post-MI patients with left ventricular systolic dysfunction, heart failure, or both Randomized, double-blind, multicenter • Captopril monotherapy • Titrated to 50 mg 3x/d • n=4,909 • Valsartan + captopril • Valsartan titrated to 80 mg 2x/d • Captopril titrated to 50 mg 3x/d • n=4,885 • Valsartan monotherapy • Titrated to 160 mg 2x/d • n=4,909 • Endpoints (follow-up mean 24.7 months): • Primary – Death from any cause during follow-up • Secondary – Death from cardiovascular causes, reinfarction, or hospitalization for heart failure N Engl J Med 2003;349:1893-906

  3. VALIANT Trial CV Death, re-MI, or hospitalization for HF* Valsartan vs captopril HR 0.95, p=0.20 Combo vs captopril HR 0.97, p=0.37 All-cause Mortality* Valsartan vs captopril HR 1.00, 97.5% CI 0.90-1.11, p=0.98 Combo vs captopril HR 0.98, 97.5% CI 0.89-1.09, p=0.73 * Met criteria for non-inferiority of valsartan vs captopril N Engl J Med 2003;349:1893-906

  4. VALIANT Trial Adverse events Valsartan vs captopril, p=NS Combo vs captopril, p<0.05 • In the valsartan group, hypotension and renal dysfunction occurred more frequently • In the captopril group, cough, rash, and taste disturbance occurred more frequently N Engl J Med 2003;349:1893-906

  5. VALIANT Trial • Among patients with myocardial infarction complicated by LV dysfunction, heart failure, or both, treatment with valsartan, an angiotensin-receptor blocker, alone or in combination with captopril, an ACE inhibitor, did not meet the primary endpoint of all cause mortality compared with captopril monotherapy for superiority • However, the trial did meet the criteria of non-inferiority for all-cause mortality and for CV death, reinfarction, or hospitalization for heart failure for valsartan vs captopril • Adverse events  in valsartan/captopril arm vs valsartan group or captopril arm

More Related